


Intended for UK healthcare professionals only



Atenza[®]XL

Methylphenidate hydrochloride prolonged-release tablets



**Bioequivalent
to Concerta[®] XL¹**



**Cost reduction
vs Concerta[®] XL²**



**Available from
All Main Wholesalers**



**Manufactured
in Europe**

Now available in the UK

For ADHD in Children (6+) and Adults³⁻⁶

Atenza[®] XL is available in four strengths:

Atenza[®] XL

18 mg

Prolonged-release
tablets (30 tablets)

Atenza[®] XL

27 mg

Prolonged-release
tablets (30 tablets)

Atenza[®] XL

36 mg

Prolonged-release
tablets (30 tablets)

Atenza[®] XL

54 mg

Prolonged-release
tablets (30 tablets)



Therapeutic indications³⁻⁶

Atenza[®] XL is indicated as part of a comprehensive treatment programme for ADHD in children aged 6 years of age and over and adults when remedial measures alone prove insufficient*.

*Treatment must be initiated and supervised by physician specialised in the treatment of ADHD such as an expert paediatrician, a child and adolescent psychiatrist or an adult psychiatrist.



Exeltis
Rethinking healthcare



Bioequivalent to Concerta® XL¹

Atenza® XL (methylphenidate prolonged release) is bioequivalent to Concerta® XL.



Cost reduction vs Concerta® XL²

Atenza® XL offers up to 65%* cost reduction compared to Concerta® XL.



Available from All Main Wholesalers

Available through AAH, Phoenix and Alliance.



Manufactured in Europe

Manufactured in Spain by Insud Pharma; the parent company of Exeltis UK.

*Price comparison based on NHS list prices (September 2025): 18 mg—Atenza XL £10.90 vs Concerta XL £31.19 (saving £20.29; 65%); 27 mg—£12.87 vs £36.81 (saving £23.94; 65%); 36 mg—£14.85 vs £42.45 (saving £27.60; 65%); 54 mg—£31.30 vs £73.62 (saving £42.32; 57%)².

1. Data on File - Bioequivalence Summary: Atenza XL vs. Concerta XL; Reference EXE-E/IPR-ATE-2280-v1;
2. NHS Business Services Authority – BNF, Drug tari, Available at: <https://bnf.nice.org.uk/drugs/methylphenidate-hydrochloride/> (Accessed: Oct 2025) 3. Atenza® XL 18mg Summary of Product Characteristics; 4. Atenza® XL 27mg Summary of Product Characteristics; 5. Atenza® XL 36mg Summary of Product Characteristics; 6. Atenza® XL 54mg Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App store. Adverse events should also be reported to Exeltis UK Limited by email to pharmacovigilance.uk@exeltis.com.